| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryoelectron Microscopy | 8 | 2022 | 91 | 1.840 |
Why?
|
| Pancreatic Neoplasms | 9 | 2021 | 645 | 1.470 |
Why?
|
| Membrane Proteins | 4 | 2023 | 1196 | 1.140 |
Why?
|
| Symporters | 2 | 2024 | 107 | 1.050 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2022 | 81 | 1.030 |
Why?
|
| Models, Molecular | 9 | 2021 | 1286 | 0.990 |
Why?
|
| Antibodies | 3 | 2022 | 350 | 0.970 |
Why?
|
| Bile Acids and Salts | 2 | 2024 | 61 | 0.900 |
Why?
|
| Chemoradiotherapy | 5 | 2019 | 301 | 0.850 |
Why?
|
| Single-Domain Antibodies | 1 | 2021 | 4 | 0.840 |
Why?
|
| Maltose-Binding Proteins | 2 | 2018 | 31 | 0.770 |
Why?
|
| Cell Surface Display Techniques | 3 | 2020 | 16 | 0.760 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 147 | 0.660 |
Why?
|
| Escherichia coli K12 | 1 | 2018 | 4 | 0.640 |
Why?
|
| Maltose | 1 | 2018 | 33 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 2438 | 0.630 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 21 | 0.630 |
Why?
|
| Molecular Probes | 1 | 2018 | 35 | 0.630 |
Why?
|
| Protein Conformation | 6 | 2022 | 881 | 0.610 |
Why?
|
| Escherichia coli Proteins | 1 | 2018 | 179 | 0.570 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 252 | 0.560 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 20 | 0.530 |
Why?
|
| Calmodulin | 1 | 2015 | 50 | 0.520 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 1169 | 0.510 |
Why?
|
| Deoxycytidine | 4 | 2017 | 237 | 0.500 |
Why?
|
| Nelfinavir | 3 | 2019 | 5 | 0.460 |
Why?
|
| Protein Binding | 5 | 2021 | 1457 | 0.450 |
Why?
|
| Fluorouracil | 2 | 2017 | 556 | 0.430 |
Why?
|
| Peptide Library | 4 | 2022 | 84 | 0.420 |
Why?
|
| Crystallography, X-Ray | 4 | 2020 | 485 | 0.420 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 263 | 0.390 |
Why?
|
| G-Protein-Coupled Receptor Kinase 1 | 2 | 2021 | 4 | 0.390 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 27 | 0.380 |
Why?
|
| Rhodopsin | 2 | 2021 | 19 | 0.370 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2009 | 46 | 0.350 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 73 | 0.350 |
Why?
|
| Capecitabine | 4 | 2019 | 96 | 0.340 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2019 | 15 | 0.340 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 108 | 0.320 |
Why?
|
| Polymers | 2 | 2020 | 202 | 0.300 |
Why?
|
| Biotinylation | 2 | 2018 | 41 | 0.290 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 276 | 0.290 |
Why?
|
| Thermodynamics | 5 | 2019 | 309 | 0.290 |
Why?
|
| DNA Damage | 2 | 2019 | 366 | 0.290 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2360 | 0.280 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2016 | 95 | 0.260 |
Why?
|
| Biological Transport | 2 | 2023 | 396 | 0.260 |
Why?
|
| Recombinant Proteins | 3 | 2019 | 1015 | 0.250 |
Why?
|
| Humans | 30 | 2024 | 86678 | 0.250 |
Why?
|
| Lipopeptides | 1 | 2024 | 16 | 0.240 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2023 | 4 | 0.240 |
Why?
|
| Amino Acid Sequence | 4 | 2021 | 2062 | 0.240 |
Why?
|
| Hepatitis B | 1 | 2024 | 74 | 0.230 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 322 | 0.230 |
Why?
|
| Mannosyltransferases | 1 | 2023 | 6 | 0.230 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 91 | 0.220 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2019 | 19 | 0.220 |
Why?
|
| Nuclear Pore | 1 | 2022 | 11 | 0.220 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2022 | 13 | 0.220 |
Why?
|
| Tryptophan | 1 | 2023 | 90 | 0.220 |
Why?
|
| RNA Transport | 1 | 2022 | 11 | 0.220 |
Why?
|
| Kinetics | 4 | 2019 | 1513 | 0.220 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 14 | 0.210 |
Why?
|
| Camelids, New World | 1 | 2021 | 3 | 0.210 |
Why?
|
| Camelus | 1 | 2021 | 5 | 0.210 |
Why?
|
| Sequence Analysis, Protein | 1 | 2021 | 28 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 1686 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 58 | 0.200 |
Why?
|
| Fungal Proteins | 1 | 2022 | 141 | 0.200 |
Why?
|
| Multiprotein Complexes | 1 | 2022 | 95 | 0.200 |
Why?
|
| GATA6 Transcription Factor | 1 | 2021 | 13 | 0.200 |
Why?
|
| Lipids | 1 | 2023 | 269 | 0.200 |
Why?
|
| Cytoplasm | 1 | 2022 | 281 | 0.200 |
Why?
|
| Mutation | 4 | 2019 | 3968 | 0.200 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 1204 | 0.200 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 503 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 64 | 0.200 |
Why?
|
| Sodium | 1 | 2022 | 341 | 0.190 |
Why?
|
| Dioxygenases | 1 | 2021 | 74 | 0.190 |
Why?
|
| Sequence Alignment | 1 | 2021 | 351 | 0.190 |
Why?
|
| Protein Engineering | 2 | 2021 | 140 | 0.190 |
Why?
|
| Frizzled Receptors | 1 | 2020 | 15 | 0.190 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 639 | 0.190 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 164 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2021 | 3243 | 0.190 |
Why?
|
| Propylamines | 1 | 2020 | 9 | 0.190 |
Why?
|
| Publications | 1 | 2020 | 27 | 0.190 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 3 | 0.180 |
Why?
|
| 5-Methylcytosine | 1 | 2021 | 112 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 388 | 0.170 |
Why?
|
| Ligands | 2 | 2018 | 433 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 383 | 0.160 |
Why?
|
| Apoproteins | 1 | 2018 | 22 | 0.160 |
Why?
|
| Radiation Dosage | 1 | 2019 | 227 | 0.160 |
Why?
|
| Antibody Affinity | 1 | 2018 | 38 | 0.160 |
Why?
|
| Metformin | 2 | 2021 | 128 | 0.160 |
Why?
|
| Substrate Specificity | 3 | 2018 | 347 | 0.160 |
Why?
|
| Protein Stability | 1 | 2018 | 99 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 429 | 0.160 |
Why?
|
| Catalysis | 3 | 2017 | 203 | 0.150 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2017 | 22 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 138 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2019 | 1538 | 0.150 |
Why?
|
| Galactose | 1 | 2016 | 32 | 0.150 |
Why?
|
| Liver | 1 | 2022 | 1230 | 0.150 |
Why?
|
| Duodenum | 1 | 2017 | 100 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 481 | 0.150 |
Why?
|
| Cell Membrane | 1 | 2020 | 666 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 51 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 199 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 339 | 0.140 |
Why?
|
| Lectins | 1 | 2016 | 84 | 0.140 |
Why?
|
| Animals | 7 | 2021 | 26589 | 0.140 |
Why?
|
| Isoxazoles | 1 | 2016 | 77 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2021 | 628 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1135 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 21 | 0.140 |
Why?
|
| Binding Sites | 4 | 2021 | 1098 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1981 | 0.140 |
Why?
|
| Pyrazines | 1 | 2016 | 92 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2017 | 156 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 557 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 395 | 0.140 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Aminopeptidases | 1 | 2015 | 17 | 0.130 |
Why?
|
| Protein Methyltransferases | 1 | 2015 | 14 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 49 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 371 | 0.130 |
Why?
|
| Histones | 1 | 2017 | 311 | 0.130 |
Why?
|
| Glycine | 1 | 2015 | 92 | 0.130 |
Why?
|
| Phosphoglycerate Mutase | 1 | 2015 | 4 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2019 | 7998 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Receptors, Prolactin | 1 | 2015 | 10 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Single-Chain Antibodies | 1 | 2015 | 17 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1208 | 0.130 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 116 | 0.130 |
Why?
|
| Leptin | 1 | 2015 | 105 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 154 | 0.120 |
Why?
|
| Epitopes | 1 | 2015 | 255 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
| Catalytic Domain | 2 | 2015 | 156 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 302 | 0.120 |
Why?
|
| Mice | 5 | 2021 | 11356 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2015 | 615 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 180 | 0.110 |
Why?
|
| Health Status | 1 | 2015 | 360 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1464 | 0.110 |
Why?
|
| Androstadienes | 1 | 2012 | 72 | 0.110 |
Why?
|
| Proteins | 1 | 2018 | 777 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 329 | 0.110 |
Why?
|
| Aged | 4 | 2019 | 18423 | 0.110 |
Why?
|
| Prednisone | 1 | 2012 | 258 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 378 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 2426 | 0.100 |
Why?
|
| Middle Aged | 5 | 2019 | 25040 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6513 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2015 | 873 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1376 | 0.100 |
Why?
|
| Male | 7 | 2019 | 40988 | 0.090 |
Why?
|
| Cell Line | 1 | 2015 | 2469 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 861 | 0.090 |
Why?
|
| Biocatalysis | 1 | 2010 | 51 | 0.090 |
Why?
|
| Butyric Acid | 1 | 2009 | 11 | 0.090 |
Why?
|
| Maleimides | 1 | 2009 | 29 | 0.090 |
Why?
|
| Insulin | 1 | 2015 | 1160 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2022 | 1106 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 279 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1037 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 416 | 0.080 |
Why?
|
| Adult | 3 | 2019 | 25659 | 0.080 |
Why?
|
| Female | 6 | 2019 | 44550 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 458 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2601 | 0.080 |
Why?
|
| Quality of Life | 1 | 2015 | 1585 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 5980 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 2 | 2021 | 736 | 0.070 |
Why?
|
| Adolescent | 1 | 2019 | 8984 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 1939 | 0.070 |
Why?
|
| United Kingdom | 2 | 2015 | 164 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 308 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2017 | 468 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3030 | 0.060 |
Why?
|
| Hepatitis Delta Virus | 1 | 2024 | 9 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2024 | 43 | 0.060 |
Why?
|
| Virus Internalization | 1 | 2024 | 39 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2024 | 74 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2024 | 127 | 0.060 |
Why?
|
| Anions | 1 | 2023 | 31 | 0.060 |
Why?
|
| Chaetomium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Glycosylation | 1 | 2023 | 129 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2023 | 166 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 63 | 0.050 |
Why?
|
| Phthalazines | 1 | 2022 | 39 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 72 | 0.050 |
Why?
|
| Spindle Apparatus | 1 | 2022 | 65 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2231 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 111 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 27 | 0.050 |
Why?
|
| Mitosis | 1 | 2022 | 153 | 0.050 |
Why?
|
| Smad4 Protein | 1 | 2021 | 23 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2021 | 37 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1721 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2903 | 0.050 |
Why?
|
| Protein Domains | 1 | 2021 | 128 | 0.050 |
Why?
|
| Cattle | 1 | 2021 | 376 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2022 | 193 | 0.050 |
Why?
|
| Epigenomics | 1 | 2021 | 100 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 314 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 1056 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2024 | 512 | 0.050 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2019 | 15 | 0.050 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2019 | 16 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2019 | 129 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2019 | 86 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 378 | 0.040 |
Why?
|
| Peptides | 1 | 2023 | 639 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 790 | 0.040 |
Why?
|
| Arrestin | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2019 | 646 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 36 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 357 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2019 | 439 | 0.040 |
Why?
|
| Zirconium | 1 | 2017 | 2 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3642 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2017 | 45 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1540 | 0.040 |
Why?
|
| Gels | 1 | 2016 | 48 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 86 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 52 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2019 | 597 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2016 | 287 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1197 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 692 | 0.030 |
Why?
|
| Switzerland | 1 | 2015 | 17 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1384 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 1284 | 0.030 |
Why?
|
| Prolactin | 1 | 2015 | 88 | 0.030 |
Why?
|
| Manganese | 1 | 2015 | 53 | 0.030 |
Why?
|
| Human Growth Hormone | 1 | 2015 | 54 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 85 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1458 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2015 | 124 | 0.030 |
Why?
|
| North America | 1 | 2015 | 180 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 174 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 190 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 146 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 916 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 110 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 176 | 0.030 |
Why?
|
| Feeding and Eating Disorders | 1 | 2015 | 173 | 0.030 |
Why?
|
| Abiraterone Acetate | 1 | 2012 | 11 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 176 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 359 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 573 | 0.030 |
Why?
|
| Cisplatin | 1 | 2014 | 612 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 150 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 770 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 594 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2768 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2015 | 1078 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1718 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 4214 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1824 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 8496 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2504 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3680 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3362 | 0.010 |
Why?
|
| United States | 1 | 2016 | 6681 | 0.010 |
Why?
|